OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomali...
OnKure Therapeutics, Inc. - Class A (OKUR)
Company Research
Source: Yahoo! Finance
-- Financing to support advancement of two next-generation PI3K a pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million. OnKure intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its next-generation PI3Ka pan-mutant-selective inhibitor candidates in breast cancer and vascular anomalies, as well as for working capital and general corporate purposes. The private placement is being led by new investor, Access Biotechnolog
Show less
Read more
Impact Snapshot
Event Time:
OKUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKUR alerts
High impacting OnKure Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
OKUR
News
- OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular AnomaliesGlobeNewswire
- OnKure Therapeutics (OKUR) had its price target lowered by HC Wainwright from $34.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
- OnKure Therapeutics (OKUR) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OKUR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sellMarketBeat
- OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
OKUR
Sec Filings
- 3/24/26 - Form 4
- 3/24/26 - Form 4
- 3/12/26 - Form S-8
- OKUR's page on the SEC website